In the United States, a coenzyme Q10 serum is almost always regulated as a cosmetic under the Federal Food, Drug, and Cosmetic Act (FD&C Act), not as a drug — provided your marketing claims stay within cosmetic boundaries.
The FDA defines a cosmetic as a product intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance, without affecting the body's structure or function. A drug, by contrast, is intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body. The distinction is not about ingredients — it's about intended use as communicated through your label, website copy, social media, and advertising.
Claims that keep a CoQ10 serum in cosmetic territory include: 'visibly reduces the appearance of fine lines,' 'helps skin look more youthful,' 'antioxidant-rich formula,' 'brightens skin's appearance,' and 'supports a radiant complexion.' These are appearance-based claims.
Claims that push a product toward drug status include: 'stimulates collagen production,' 'repairs DNA damage,' 'reverses cellular aging,' 'treats wrinkles,' or 'boosts cellular energy production in skin cells.' These imply physiological action and are the kind of language that triggers FDA warning letters. The FDA has issued warning letters to cosmetic brands specifically for CoQ10 products making cellular or anti-aging mechanism claims.
Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which is the most significant overhaul of U.S. cosmetics law in decades, cosmetic manufacturers and brand owners must now register their facilities with the FDA and list their products, including ingredient information. This registration requirement applies to products manufactured or processed in the U.S. and to importers. Your contract manufacturer typically handles facility registration; product listing is the brand owner's responsibility.
For EU exports, a CoQ10 serum is regulated under EU Cosmetics Regulation 1223/2009 as a cosmetic product. There is no pre-market approval required, but a CPSR completed by a qualified safety assessor and notification through the CPNP portal are mandatory before the product is placed on the market. The Responsible Person (an EU-based legal entity) bears regulatory accountability.
The practical takeaway: have a regulatory consultant or your contract manufacturer's compliance team review your label and marketing copy before launch. The cost of a 30-minute regulatory review ($150–$400) is trivial compared to the cost of a product recall or FDA warning letter response. AJ Cosmo Labs connects founders with manufacturers who have in-house regulatory teams or established relationships with cosmetic regulatory consultants, so this step doesn't fall through the cracks.
Ingredients in this answer: Coenzyme Q10
Read the full guide on Private Label CoQ10 Serum Manufacturer – Low MOQ →